Growth Metrics

Palisade Bio (PALI) Non-Current Debt (2013 - 2020)

Palisade Bio (PALI) reported Non-Current Debt of $94000.0 for Q4 2020, down 96.31% on a QoQ basis from $2.5 million in Q1 2016.

Palisade Bio (PALI) has 5 years of Non-Current Debt data on file, last reported at $94000.0 in Q4 2020.

  • Quarterly Non-Current Debt changed N/A year-over-year to $94000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $94000.0 (changed N/A YoY) and the FY2020 annual result came in at $94000.0, changed N/A from the prior year.
  • Non-Current Debt slipped to $94000.0 in Q4 2020 per PALI's latest filing, from $2.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $2.5 million in Q1 2016 and bottomed at $94000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Palisade Bio 439.25 Mn 309.68 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 94,000.00
Dec 31, 2020 94,000.00
Mar 31, 2016 2.55 Mn
Mar 31, 2016 2.55 Mn
Dec 31, 2015 3.38 Mn
Dec 31, 2015 3.38 Mn
Sep 30, 2015 4.63 Mn
Sep 30, 2015 4.63 Mn
Jun 30, 2015 5.81 Mn
Jun 30, 2015 5.81 Mn
Mar 31, 2015 6.95 Mn
Mar 31, 2015 6.95 Mn
Dec 31, 2014 8.06 Mn
Dec 31, 2014 8.06 Mn
Sep 30, 2014 2.61 Mn
Sep 30, 2014 2.61 Mn
Jun 30, 2014 3.42 Mn
Jun 30, 2014 3.42 Mn
Mar 31, 2014 4.19 Mn
Mar 31, 2014 4.19 Mn
Dec 31, 2013 4.93 Mn
Dec 31, 2013 4.93 Mn
Sep 30, 2013 5.66 Mn
Sep 30, 2013 5.66 Mn
Jun 30, 2013 6.36 Mn
Jun 30, 2013 6.36 Mn
Mar 31, 2013 7.04 Mn
Mar 31, 2013 7.04 Mn